Veliparib

Generic Name
Veliparib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C13H16N4O
CAS Number
912444-00-9
Unique Ingredient Identifier
01O4K0631N
Indication

与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Associated Conditions
-
Associated Therapies
-

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

First Posted Date
2014-10-15
Last Posted Date
2021-02-26
Lead Sponsor
AbbVie
Target Recruit Count
595
Registration Number
NCT02264990
Locations
🇨🇿

Multiscan s.r.o. /ID# 132689, Pardubice, Czechia

🇩🇪

Klinik Loewenstein GmbH /ID# 131925, Löwenstein, Germany

🇹🇷

Inonu University /ID# 136569, Malatya, Turkey

and more 137 locations

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

First Posted Date
2014-06-16
Last Posted Date
2024-02-23
Lead Sponsor
AbbVie
Target Recruit Count
509
Registration Number
NCT02163694
Locations
🇺🇸

University of Illinois - Chicago /ID# 127576, Chicago, Illinois, United States

🇺🇸

Allegheny General Hospital /ID# 135094, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Pittsburgh MC /ID# 125005, Pittsburgh, Pennsylvania, United States

and more 216 locations

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

First Posted Date
2014-06-02
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
447
Registration Number
NCT02152982
Locations
🇺🇸

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Katmai Oncology Group, Anchorage, Alaska, United States

and more 393 locations

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

First Posted Date
2014-04-08
Last Posted Date
2020-11-17
Lead Sponsor
AbbVie
Target Recruit Count
970
Registration Number
NCT02106546
Locations
🇺🇸

Winship Cancer Institute of Emory University /ID# 124061, Atlanta, Georgia, United States

🇺🇸

Parkland Health and Hosp Syste /ID# 128518, Dallas, Texas, United States

🇺🇸

Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 128385, Dallas, Texas, United States

and more 222 locations

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

First Posted Date
2014-01-13
Last Posted Date
2016-09-27
Lead Sponsor
AbbVie
Target Recruit Count
47
Registration Number
NCT02033551
Locations
🇪🇸

Site Reference ID/Investigator# 117451, Madrid, Spain

🇺🇸

Site Reference ID/Investigator# 117415, San Antonio, Texas, United States

🇳🇱

Site Reference ID/Investigator# 117338, Maastricht, Netherlands

and more 2 locations

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

First Posted Date
2014-01-10
Last Posted Date
2021-01-20
Lead Sponsor
AbbVie
Target Recruit Count
634
Registration Number
NCT02032277
Locations
🇺🇸

Lehigh Valley Health Network /ID# 133372, Allentown, Pennsylvania, United States

🇺🇸

Texas Oncology - Medical City Dallas /ID# 126141, Dallas, Texas, United States

🇺🇸

UT Southwestern Medical Center /ID# 133849, Dallas, Texas, United States

and more 155 locations

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

First Posted Date
2013-07-25
Last Posted Date
2020-07-15
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
34
Registration Number
NCT01908478
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

First Posted Date
2013-05-15
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie
Target Recruit Count
71
Registration Number
NCT01853306

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

First Posted Date
2013-04-09
Last Posted Date
2023-09-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
208
Registration Number
NCT01827384
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

and more 5 locations

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

First Posted Date
2013-03-26
Last Posted Date
2019-10-28
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
9
Registration Number
NCT01818063
Locations
🇺🇸

Walter Reed National Military Medical Center, Bethesda, Maryland, United States

🇺🇸

Reading Hospital, Reading, Pennsylvania, United States

🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath